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Abstract
Background: Nucleotide-actived P2Y receptors play critical roles in the growth of tumor cells by regulating cellular
proliferation, differentiation and survival.
Results: Here we demonstrate that an avian P2Y purinoceptor (tP2YR) with unique pharmacological and signal
transduction properties induces morphologic and growth transformation of rodent fibroblasts. tP2YR induced a
transformed phenotype similar to the mas oncogene, a G protein-coupled receptor which causes transformation
by activation of Rac-dependent pathways. tP2YR-transformed cells exhibited increased steady-state activation of
Rac1 and RhoA. Like activated Rho GTPases, tP2YR cooperated with activated Raf and caused synergistic
transformation of NIH3T3 cells. Our data indicate that the ability of tP2YR to cause transformation is due to its
unique ability among purinergic receptors to simultaneously activate Gaq and Gai. Co-expression of constitutively
activated mutants of these two Ga subunits caused the same transformed phenotype as tP2YR and Mas.
Furthermore, transformation by both tP2YR and Mas was blocked by pharmacological inhibition of GaI by pertussis
toxin (PTX) indicating an essential role for Gai in transformation by these G-protein coupled receptors.
Conclusions: Our data suggest that coordinated activation of Gaq and Gai may link the tP2YR and possibility the
Mas oncogene with signaling pathways resulting in activation of Rho family proteins to promote cellular
transformation.
Background
Extracellular nucleotides such as adenosine 5’-tripho-
sphate (ATP), adenosine 5’-diphosphate (ADP), uridine
5’-diphosphate (UDP) and uridine 5’-triphosphate (UTP)
interact with purinergic receptors to modulate a broad
spectrum of physiological responses [1]. Purinoceptors
can be divided based on their pharmacological profiles
into two major types: P1- and P2-purinoceptors [2].
Additionally, P2 receptors can be further subdivided
into P2X-purinergic receptors which form ligand gated
ion channels and P2Y-purinergic receptors which couple
to heterotrimeric G-proteins. Most commonly, P2Y
receptors activate phospholipase C (PLC) but some also
inhibit or stimulate adenylyl cyclase or modulate ion
channel activity [3].
While the majority of studies indicate that activation
of purinergic receptors inhibits tumor growth, some
recent data suggest cell context-dependent differences
where in some instances purinergic receptors may con-
tribute to tumorigenesis. For example, multiple P2
receptor subtypes have been identified in a variety of
transformed cell lines and human tumors and activation
of these receptors regulates apoptosis, proliferation and
differentiation [4]. Consequently, depending on the
combination of purinoceptors expressed in a tumor cell
line and the second messenger pathways stimulated
upon activation, addition or release of ATP could poten-
tially promote or inhibit tumor growth [4-6]. For
instance, expression of P2Y1 receptors can inhibit and
P2Y2 receptor stimulate proliferation of a melanoma cell
line in response to ATP [7]. In addition to its growth
promoting activity in melanomas, stimulation of P2Y2
receptors can stimulate cell proliferation in lung, breast,
ovarian and endometrial cell lines [8-11]. In addition to
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mutated P2Y2 receptor has been isolated in an expres-
sion screen to identify potential transforming genes
expressed in a colorectal cancer cell line [12]. The onco-
genic potential of this mutated P2Y2 receptor was con-
firmed in focus formation, soft agar and tumorigenicity
assays in nude mice.
P2Y-purinoceptors can regulate a complex network of
signaling pathways that may contribute to transforma-
tion. P2Y receptors can couple to Gaq or Gai stimulat-
ing PLC either by activation of Gaq or release of Gbg
following Gai activation [13]. Furthermore, increases in
the activity of multiple kinases, which can promote pro-
liferation have been reported following stimulation of
P2Y receptors. These include Pyk2, protein kinase C
(PKC), and the ERK, p38 and JNK mitogen-activated
protein kinase cascades [13]. In addition, an RGD
domain in P2Y2 links this receptor to activation of G12/
13 and Go stimulating RhoGEF/Rho and RacGEF/Rac1,
respectively [14,15]. While numerous second messenger
pathways can be activated by P2Y receptors, the path-
ways that contribute to the promotion of a transformed
phenotype remain unexplored.
Other G-protein coupled receptors (GPCR) oncogenes
cause tumorigenic transformation of NIH3T3 cells by
activating Rho family proteins [16]. Rho proteins are
members of the Ras superfamily of small GTPases that
function as GDP/GTP-regulated molecular switches to
modulate a variety of cellular processes including actin
cytoskeletal organization, gene transcription and cell
cycle progression [17,18]. Specific Rho family proteins
regulate the reorganization of distinct actin cytoskeletal
structures. Cdc42 stimulates the formation of filopodia,
Rac1 formation of lamellipodia and membrane ruffling
and RhoA formation of actin stress fibers and focal
adhesions [19]. Rho family proteins themselves can
cause tumorigenic transformation of rodent fibroblasts
and mediate transformation by a number of oncogenes
including Ras and Dbl [20]. A number of studies indi-
cate that transformation by GPCRs is also dependent on
Rho family proteins [16]. For example, Mas transforma-
tion is dependent on Rac1 function [21], whereas, G2A,
Par-1, and M1 acetylcholine receptor transformation is
mediated in part by activation of RhoA or a RhoA-
related protein [22-24].
We cloned an avian P2Y purinergic receptor (tP2YR)
which shows strongest amino acid sequence identity
with the mammalian UTP-selective P2Y4 receptor [25].
tP2YR has a unique pharmacological profile [26]. It is
preferentially activated by nucleoside triphosphates and
exhibits low affinity for nucleoside diphosphates. How-
ever, it displays no selectivity for the nucleotide base
moiety being activated by UTP, UTP, GTP, CTP, ITP
and XTP. Furthermore, in addition to stimulating PLC
through the Gaq/11 class of heterotrimeric G-proteins,
activation of tP2YR also results in pertussis toxin-sensi-
tive inhibition of adenylyl cyclase indicating that this
receptor also has the unique ability among purinocep-
tors to simultaneously couple to Gaq and Gai [25,26].
During the course of our characterization of tP2YR, we
observed that this receptor induced striking morpholo-
gic transformation of 1321N1 astrocytoma cells prompt-
ing us to determine whether the tP2YR could cause
morphologic and growth transformation of NIH3T3
cells. We found that tP2YR caused activation of Rho
family proteins and requires the simultaneous activation
of both Gaq and GaI for transformation. We propose
that this purinergic receptor stimulates cell growth and
transformation through the coordinated activation of
both Gaq and Gai-dependent signaling pathways result-
ing in activation of Rho family proteins.
Results
Expression of the tP2YR induces altered cell morphology
in 132N1 astrocytoma cells
To study the pharmacological selectivity of tP2YR, we
generated a number of clonal 1321N1 human astrocy-
toma cell lines stably infected with a retrovirus expres-
sion vector encoding the tP2YR. Surprisingly, a number
of these cell lines exhibited an unusual morphologic and
growth alteration not observed with the expression of
other purinergic receptors in 1321N1 cells (data not
shown). While vector-infected cells were unchanged in
appearance from control untransfected 1321N1 cells
and formed confluent monolayers of cells, the tP2YR-
expressing cells displayed an elongated morphology and
showed string-like patterns and cell clusters (Figure 1).
Furthermore, the analyses of multiple, independent clo-
nal cell lines indicated that this altered morphology
Figure 1 Expression of tP2YR in 1321N1 astrocytoma cells
results in an altered cell morphology. 1321N1 cells were stably
infected with expression constructs encoding either tP2YR or empty
retrovirus vector as indicated (1000× magnification).
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(data not shown). This ability to cause morphological
transformation of the 1321N1 astrocytoma cell line was
unique among the numerous receptors that we have
evaluated previously, including the mammalian P2Y2
receptor (Boyer and Harden, unpublished observation).
Expression of tP2YR causes transformation of NIH3T3
cells
The altered morphology of tP2YR-expressing 1321N1
cells suggested that this GPCR may exhibit transforming
properties. To investigate this hypothesis further, we
determined if the tP2YR could also cause transformation
NIH3T3 cells, a nontransformed immortalized mouse
fibroblast cell line that we and others have shown to be
sensitive to morphologic and growth transformation by
Rho GTPase activation [27]. This experimental paradigm
has provided a sensitive assay to detect the transforming
activity of other GPCR oncoproteins and has been
instrumental in dissecting the signal transduction path-
ways responsible for their transforming activity [21-24].
Using a focus formation assay, we found that transfec-
tion of pZIP-tP2YR in to NIH3T3 cells caused the
appearance of foci of transformed cells (Figure 2A).
Interestingly, the appearance of these foci was distinct
from the foci caused by activated Ras(61L), which are
comprised of highly refractile, elongated cells and
instead were similar to those caused by activated RhoA
(63L), which are comprised of densely-packed, nonrefra-
tile cells. Furthermore, tP2YR-induced foci were similar
in appearance to those induced by two other transform-
ing GPCRs that cause transformation by activation of
either Rac1-dependent (Mas) or RhoA-dependent (G2A)
signaling pathways [21,22].
To determine if overexpression of the tP2YR reduced
the requirement of NIH3T3 cells for serum growth fac-
tors, tP2YR-expressing cells were plated at low density
in growth medium supplemented with 10% calf serum.
After 24 hours, the cultures were switched to growth
media supplemented with 10%, 2% or 0.5% calf serum.
Untransformed NIH3T3 cells require growth medium
supplemented with 10% calf serum for efficient growth
in culture. As expected, cells transformed by activated
Ras continue to proliferate in 2% or 0.5% serum,
whereas vector-transfected control cells exhibited very
limited proliferation in growth medium supplemented
with 2% or 0.5% serum (Figure 2B). Similar to activated
Ras-expressing cells, tP2YR-expressing cells formed
d e n s ec o l o n i e se v e ni n0 . 5 %s e r u m ,i n d i c a t i n gt h a t
expression of the tP2YR can reduce the growth require-
ment of NIH3T3 cells for serum growth factors.
To further characterize the ability of tP2YR to cause
growth transformation of NIH3T3 cells, we assessed the
ability of tP2YR-expressing cells to exhibit anchorage-
and serum-independent growth. For these experiments,
we isolated NIH3T3 cells stably transfected with expres-
sion constructs encoding either H-Ras(61L), RhoA(63L),
Mas, tP2YR, or the pZIP-NeoSV(x)1 empty vector con-
trol. Following selection in growth medium supplemen-
ted with G418, multiple antibiotic-resistant colonies
(>100) were pooled together to establish stable cell lines
to be used for these analyses. To assay the ability of the
tP2YR expressing cells to exhibit anchorage-independent
growth, each pooled cell line was suspended in soft
agar. As described previously, cells expressing activated
Ras or RhoA formed colonies in soft agar [28] and Fig-
ure 2C). The tP2YR-expressing cells also readily formed
colonies in soft agar indicating that expression of tP2YR
can cause anchorage-independent growth. Interestingly,
tP2YR-expressing colonies were similar in size and mor-
phology to those formed by Mas-transformed cells. For
example, these colonies did not spread laterally in the
agar as mutant Ras-expressing colonies, but instead
formed clusters of cells that protruded out of the plane
of the agar.
Similar to activators of Rho family proteins, tP2YR
cooperates with activated Raf1 in focus formation assays
The morphological appearance of the tP2YR-induced
foci suggested that tP2YR might cause transformation
by activation of Rho family proteins. One well-character-
ized property of transformation by Rho proteins and
their activators is their ability to cooperate with acti-
vated Raf-1 to cause synergistic transformation of
NIH3T3 cells [28-32]. To determine if tP2YR could also
cooperate with activated Raf-1, plasmids encoding acti-
vated Raf-1(340D) were co-transfected at concentrations
that resulted in very low, or no, focus-formation along
with either tP2YR, activated Rac1(115I) as a positive
control, or the empty vector negative control. As we
observed previously, co-expression of activated Rac1
(115I) with Raf-1(340D) caused a 100-fold enhancement
of focus-forming activity over that seen with expression
of Rac1(115I) or Raf alone [28]. Similarly, as shown in
Figure 3A, co-transfection of tP2YR with activated Raf
caused a 15- to 20-fold synergistic enhancement of
focus-forming activity. These results indicate that like
activators of Rho proteins, tP2YR can cooperate in a
focus formation assay with activated Raf-1.
In addition to increasing the number of tP2YR-
induced foci, co-expression with activated Raf altered
the morphology of the transformed foci (Figure 3B). As
described previously, co-expression of activated Raf-1
with either RhoA or G2A causes the appearance of
transformed foci that are similar to those caused by acti-
vated Ras and contain elongated, highly refractile cells
[21]. In contrast, co-transfection of activated Rac1 or
Mas with activated Raf-1 caused the appearance of foci
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non-refractile appearance [21]. The transformed foci
caused by co-expression of Raf-1 and tP2YR were indis-
tinguishable in appearance from those caused by expres-
sion of activated Raf-1 and either activated Rac1 or Mas,
suggesting that tP2YR may activate Rac1.
tP2YR causes activation of both Rac1 and RhoA
The appearance of tP2YR foci suggests that it causes
transformation by activation of Rac1 or a related
protein. To address this possibility, we assessed the abil-
ity of tP2YR to activate Rac1 and RhoA in pull-down
assays. These assays take advantage of the increased affi-
nity of activated Rac1 or RhoA for the isolated Rac/Rho
binding domains (RBDs) of Pak and Rhotekin, effectors
of Rac and RhoA, respectively. For these experiments,
NIH3T3 cells were transfected with either pcDNA3 or
tP2YR along with either Tiam1-C1199 (positive control
for Rac1 activation) or Ect2-DH/PH/C (positive control
for RhoA activation). Cell lysates were incubated with
Figure 2 Expression of tP2YR causes tumorigenic transformation of NIH3T3 cells. A. Expression of tP2YR in NIH3T3 cells induces the
formation of transformed foci. NIH3T3 cells were transfected with empty vector, H-Ras(61L) or RhoA(63L), the Mas Oncogene or tP2YR. The
appearance of foci of transformed cells was evaluated 14 to 16 days after transfection (40× magnification). B. tP2YR-expressing NIH3T3 cells
exhibit serum independent growth. NIH3T3 cells stably-transfected with the empty vector or encoding activated H-Ras(61L) or tP2YR were plated
at a density of 10
3 cells per 60 mm dish in growth medium supplemented with 10% calf serum. After 24 hr, the growth medium was changed
to media supplemented with 0.5%, 2% or 10% calf serum. The cultures were then maintained for 2 weeks and stained with 4% crystal violet to
better visualize the cells. C. tP2YR-expressing NIH3T3 cells show anchorage-independent growth. NIH3T3 cells stably-transfected with pZIP-NeoSV
(x)1 retrovirus vectors encoding the indicated proteins were plated in soft agar at a density of 10
3 [for Ras(61L)] or 10
4 [for RhoA(63L), Mas and
tP2YR)] cells per 60 mm dish. The appearance of colonies of proliferating cells was evaluated after 3 weeks (40× magnification).
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kin-RBD to assess RhoA activation. As shown in Figure
4B and 4C, expression of tP2YR increased activation of
both Rac1 and RhoA. These data indicate that tP2YR
can cause activation of Rho family proteins.
The tP2YR causes transformation by coordinated
activation of Gai and Gaq
We next investigated which Ga subunit(s) may link
tP2YR to Rho protein activation. P2Y-purinergic
receptors can couple to either Gaq, activating PLC or to
Gai inhibiting adenylyl cyclase activity. Typically puri-
nergic receptors do not couple to both of these G-pro-
teins. However, our previous studies indicated that this
tP2YR has the unique ability to robustly activate both
Gaq and Gai [25,26]. Therefore, we sought to determine
if activation of either or both of these Ga subunits may
contribute to tP2YR transforming activity by examining
the ability of constitutively activated mutants of Gai
and Gaq e i t h e r ,a l o n e ,o ri nc o m b i n a t i o n ,t oc a u s e
Figure 3 tP2yR synergizes with activated Raf1 to induce foci with similar characteristics to activated Rac1. A. Quantitation of the
number of foci induced when tP2YR or activated Rac1(115I) were co-transfected with activated Raf-1(340D). NIH3T3 cells were co-transfected
with 1 μg of pZIP-NeoSV(x)1 retrovirus expression plasmids encoding tP2YR or Rac1(115I) and either 1 μg of the empty pZIP-NeoSV(x)1 plasmid
DNA (-) or encoding the weakly activated Raf-1(340D) mutant (+). The appearance of foci of transformed cells was quantitated after 14 days.
Data shown are the mean ± standard error for triplicate plates and are representative of three independent assays. B. The appearance of
transformed foci induced in NIH3T3 cells were co-transfected with activated Raf-1(340D) is similar to those induced by activated Rac(115I) and
distinct from those induced by activated Rho(63L). pZIP-NeoSV(x)1 expression vectors encoding RhoA(63L), G2A, Mas, Rac1(115I) or tP2YR were
co-transfected with pZIP-raf-1(340D). pZIP-H-ras(61L) was co-transfected with the empty pZIP-NeoSV(x)1 plasmid DNA. The appearance of foci of
transformed cells was monitored 14 days after transfection (40× magnification).
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alone, neither activated Gai, nor activated Gaq caused
the appearance of transformed foci in our NIH3T3 cells
(data not shown). However, co-expression of activated
Gai and Gaq caused the appearance of transformed foci
that were identical in appearance to those induced by
the tP2YR or Mas (Figure 5A). These results suggested
that the coordinate activation of both Gai and Gaq by
the tP2YR maybe responsible for its transforming
activity.
To examine the requirement for Gai activation for
focus formation by these GPCR oncogenes, NIH3T3
cells were transfected with expression constructs encod-
ing either Mas, tP2YR, G2A, or Ras(61L) and the trans-
fected cultures were maintained in the presence or
absence of PTX to inactivate Gai. Treatment of cells
with PTX caused a 90% inhibition of Mas- and tP2YR-
induced focus-formation (Figure 5B). In contrast, PTX
treatment did not cause any reduction in oncogenic
Ras-induced focus formation, indicating that the reduc-
tion seen with tP2YR was not due to nonspecific inhibi-
tion by PTX. Interestingly, PTX also caused a 60%
reduction in G2A-induced focus-formation. We pre-
viously showed that G2A causes transformation by acti-
vation of Ga13, which in turn causes activation of RhoA
by stimulation of the Lsc/p115 RhoGEF [22,23]. These
data suggest that GPCR oncogenes such as Mas, tP2YR
a n dt oal e s s e re x t e n tG 2 Ar e l yo nG ai activity for
induction of a transformed phenotype.
Discussion
Purinergic receptors regulate a number of physiological
functions and recent data indicate that purinergic signal-
ing may also play an important role in both the promo-
tion and inhibition of tumor growth [4,5]. Here we
present evidence that an avian P2Y purinoceptor
(tP2YR) with unique pharmacological and signal trans-
duction properties induces morphologic and growth
transformation. tP2YR expressing NIH3T3 cells exhib-
ited loss of density-dependent inhibition of growth, pro-
liferated in the absence of attachment to the
substratum, and displayed a reduced requirement for
serum growth factors. Furthermore, our analyses suggest
that the tP2YR causes transformation by activation of
Rho proteins. The foci caused by tP2YR expression are
identical in appearance to those caused by another
transforming GPCR, Mas that causes transformation by
activation of Rac-dependent signaling pathways [21].
Furthermore, tP2YR causes activation of both Rac1 and
RhoA in an in vitro biochemical assay. Finally, we pre-
sent data suggesting that tP2YR, as well as Mas, cause
transformation by coordinate activation of Gai and Gaq.
tP2YR causes transformation by activation of Rho
proteins
While our in vitro Rac1 and RhoA activation assays
indicate that tP2YR can activate both Rho family pro-
teins, based on the appearance of transformed foci we
favor the interpretation that activation of Rac1 (or a
related protein) maybe more important for the trans-
formed phenotype induced by tP2YR. For example, the
appearance of tP2YR-induced foci was identical to those
induced by expression of the Mas oncogene, which
causes transformation by activation of Rac1 rather than
RhoA [21]. In contrast, G-proteins and GPCRs such as
Ga12/13 and G2A cause the appearance of Rho-like foci
and require RhoA protein function for transformation
[22-24,33,34]. Additionally, tP2YR cooperated with acti-
vated Raf in a focus formation assay causing the appear-
ance of foci that resemble those by activated Raf plus
Rac1 or Rac1 activators such as Mas [21]. This is in
contrast to the appearance of foci induced by activated
Raf plus RhoA or RhoA activators such as G2A [22].
These data suggest that while tP2YR is capable of acti-
vating both Rac1 and RhoA in an in vitro biochemistry
assay; the morphologically predominant phenotype
Figure 4 Expression of tP2YR results in lamellipodia formation and activation of both Rac1 and RhoA. NIH3T3 cells were transiently
transfected with either empty pcDNA3 expression vector or those encoding tP2YR, Tiam1-C1199 (A, potent activator of Rac1) or Ect2-DH/PH/C
(B, potent activator of RhoA). Activated GTP-bound Rac1 and RhoA were isolated in pull-down assays with GST-Pak-PBD and GST-Rhotekin-RBD,
respectively.
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vation maybe more important for the transforming
activity of this oncogene.
tP2YR causes transformation by the coordinated
activation of both Gai and Gaq
Treatment of cells with ATP can influence cell growth
and proliferation in opposing ways depending on the
cell type and the combination of purinoceptors
expressed. In rare instances, stimulation of P2Y recep-
tors can promote cellular proliferation and oncogenic
transformation [5,6,12,13]. Since the ability of tP2YR to
cause tumorigenic transformation is unique among the
receptors that we have characterized, the possibility
r e m a i n st h a tt h i sa v i a nr e c e p t or is constitutively acti-
vated. One characteristic of the tP2YR that sets it apart
from other purinoceptors is its ability to simultaneously
activate both Gai and Gaq [25,26]. This observation
prompted us to test the hypothesis that transformation
by tP2YR maybe due to the coordinated activation of
both Gai and Gaq. We found that while neither Gai
nor Gaq when expressed alone in NIH3T3 cells induced
Figure 5 Transformation of NIH3T3 cells by tP2YR is caused by coordinated activation of Gai and Gaq. A.G ai and Gaq cooperate and
cause the appearance of transformed foci similar to those caused by tP2YR. NIH3T3 cells were transfected with pZIP-NeoSV(x)1 expression
vectors encoding tP2YR or Mas, or co-transfected with vectors encoding constitutively activated mutants of GaI2(QL) and Gaq(QL). The
appearance of foci of transformed cells was monitored 3 weeks after transfection (40× magnification). B. Transformation by tP2YR and Mas
requires Gai protein function. NIH3T3 cells were transfected with pZIP-NeoSV(X)1 expression vectors encoding H-Ras(61L) (25 ng per 60 mm
dish), G2A (2 μg per dish), tP2YR (2 μg per dish) or Mas (1 μg per dish). Cultures were then maintained in growth medium (-) or medium
supplemented with 100 ng per ml PTX (+) for 14 to 16 days after which the number of foci were quantitated. Data shown are expressed as the
mean of the percent of the total number of foci in the untreated dishes ± standard error and are representative of two separate assays
performed in triplicate.
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induced the appearance of transformed foci. Further-
more, the morphology of Gai and Gaq induced foci was
identical to those induced by expression of either tP2YR
or Mas indicating that similar pathways may be acti-
vated to promote transformation. While previous studies
have demonstrated only a mild focus formation activity
of Gaq in NIH3T3 cells [35], others indicate that Gaq
expression induces apoptotic cell death [36,37], we have
been able to establish stable cell lines that express Gaq
using a relatively weak cytomegalovirus promoter
(pcDNA3). Furthermore, focus formation was not
observed in these stable cell lines indicating that Gaq
expression alone is not transforming in the NIH3T3
strain used in these studies. Nor was Gaq transforming
when co-expressed with activated Raf (data not shown).
Finally, focus formation by both Mas and tP2YR
requires Gai activity supporting the hypothesis that it is
the coordinated activation of these two Ga subunits,
which leads to growth transformation by these GPCR
oncoproteins.
How coordinated activation of Gai and Gaq by tP2YR
leads to activation of Rho proteins remains unknown.
The mammalian P2Y2 receptor can activate both RhoA
and Rac1 through interaction with integrins mediated
by an RGD sequence motif located in the first extracel-
lular loop of the receptor [13]. The interaction of the
P2Y2 receptor with integrins is necessary for coupling to
Gao leading to activation of Rac1 and Ga12 and to acti-
vation of RhoA but is not required for activation of Gaq
[14]. Since, the tP2YR does not contain an RGD
sequence, it is likely that activation of Rho proteins are
mediated by this alternative pathway. Previous studies
have found that the activation of Gai and Gaq by
expression of multiple P2Y receptors on the same cell
can cause a synergistic rise in second messenger produc-
tion [13]. It is possible that this synergistic activation of
second messengers can lead to Rho activation.
Conclusions
Our data suggest that overexpression of the tP2YR
causes growth transformation of NIH3T3 cells via a
coordinate activation of Gai and Gaq, leading to activa-
tion of Rho proteins. These studies provide novel insight
into the mechanism by which GPCR signaling can pro-
mote tumorigenesis.
Methods
Molecular constructs
The tP2YR mammalian retrovirus expression construct
pLXSN-tP2YR has been described previously [25]. pZIP-
NeoSV(x)1 retrovirus expression vectors encoding wild
type Mas, and the constitutively activated and trans-
forming Rac1(61L), Rac1(115I), H-Ras(61L), RhoA(61L),
or Raf-1(340D) mutant proteins and pCDNA3 expres-
sion vectors encoding GTPase-deficient, constitutively
activated mutants of Gaq(QL), Gai(QL), Rac1(12V), and
RhoA(12V) have also been described previously [38,39].
Cell culture and transformation assays
1 3 2 1 N 1h u m a na s t r o c y t o m ac e l l sw e r eg r o w ni nD u l -
becco’s minimum Eagle’s medium (DMEM) supplemen-
ted with 5% fetal calf serum. Infection of 1321N1
astrocytoma cells was done as described [25]. NIH3T3
mouse fibroblasts were grown in DMEM supplemented
with 10% calf serum and transfected as described pre-
viously [40]. For focus formation assays, 60 mm dishes
were transfected and maintained in growth medium for
three weeks. Individual foci were either photographed
and/or stained with 0.4% crystal violet before quantita-
tion. To evaluate the ability of pertussis toxin (PTX)
treatment to inhibit transformation, focus formation
assays were performed as above in growth medium sup-
plemented with 100 ng/ml of PTX (Sigma). Growth
medium and PTX were replaced every other day for 14-
16 days. For generation of stable cell lines, transfected
cultures were maintained in growth medium supple-
mented with 400 μg/ml G418 (Geneticin; GIBCO-BRL)
and following selection, multiple G418-resistant colonies
(>100) were pooled. Assays to examine growth in soft
agar and low serum have been described previously [41].
Rac1 and RhoA activation assays
Assays to determine cellular Rac1-GTP and RhoA-GTP
levels were performed as described previously [42,43].
Briefly, NIH3T3 cells were transiently transfected with
either empty pcDNA3 expression vector or those encod-
ing tP2YR, the C-terminal 1199 amino acids of Tiam-1,
C1199 [44] or the DH/PH/C domain of Ect2 [45], using
Lipofectamine Plus Reagent (Invitrogen Inc.). Cells were
grown for 24 h in DMEM supplemented with 0.5% fetal
calf serum. Cell lysates were incubated with GTP-depen-
dent binding domains for Pak1 (GST-PAK-RBD) or
Rhotekin (GST-Rhotekin-RBD) as we have described
previously [42,43].
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